Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1485-1490

  De Bruin, M ^a   Van Capel, T ^a   Smid, K ^a   Van Der Born, K ^a   Fukushima, M ^b   Hoekman, K ^a   Pinedo, H M ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Deoxyribose 1 phosphate; Fluoropyrimidines; Platelet derived endothelial cell growth factor; Thymidine phosphorylase

Indexed keywords

CAPECITABINE; DEOXYRIBOSE; DEOXYRIBOSE 1 PHOSPHATE; DOXIFLURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE; TRIFLURIDINE; UNCLASSIFIED DRUG;

CATALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; SOLID TUMOR;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROURACIL; HUMANS; INHIBITORY CONCENTRATION 50; NEOPLASMS; PYRIMIDINES; RIBOSEMONOPHOSPHATES; THYMIDINE PHOSPHORYLASE; TIME FACTORS; TRANSFECTION;

EID: 10344262925     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027702     Document Type: Conference Paper

References (7)

1. Ackland, S.P.; Peters, G.J. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist. Updat. 1999, 2, 205-214.
2. Miwa, M.; Ura, M.; Nishida, M.; Sawada, N.; Ishikawa, T.; Mori, K.; Shimma, N.; Umeda, I.; Ishitsuka, H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer 1998, 34, 1274-1281.
3. 3Thd and its modulator (1): functional mechanims of the cytotoxicity of AS-102 effective against FUra-resistant tumors. Proc. Am. Assoc. Cancer Res. 1998, 39, (# 3187).
4. Fukushima, M.; Suzuki, N.; Emura, T.; Yano, S.; Kazuno, H.; Tada, Y.; Yamada, Y.; Asao, T. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′- deoxyribonucleosides. Biochem. Pharmacol. 2000, 59, 1227-1236.
5. Thomas, M.B.; Hoff, P.M.; Carter, S.; Bland, G.; Lassere, Y.; Wolff, R.; Xiong, H.; Hayakawa, T.; Abbruzzese, J. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/antiangiogenic agent given orally on a once-daily schedule for five days every three weeks in patients with solid tumors. Proc. Am. Assoc. Cancer Res. 2002, 43, 554 (#2754).
6. De Bruin, M.; Van Capel, T.; Van Der Born, K.; Kruyt, F.A.; Fukushima, M.; Hoekman, K.; Pinedo, H.M.; Peters, G.J. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br. J. Cancer 2003, 88, 957-964.
7. De Bruin, M.; Smid, K.; Laan, A.C.; Noordhuis, P.; Fukushima, M.; Hoekman, K.; Pinedo, H.M.; Peters, G.J. Rapid disappearance of deoxyribose-1-phosphate in platelet derived endothelial cell growth factor/thymidine phosphorylase overexpressing cells. Biochem. Biophys. Res. Commun. 2003, 301, 675-679.